Cart
sales@molnova.com
Sutimlimab
CAS No. 2049079-64-1
Sutimlimab( —— )
Catalog No. M36674 CAS No. 2049079-64-1
Sutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemolysis.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 471 | In Stock |
|
| 10MG | 755 | In Stock |
|
| 25MG | 1121 | In Stock |
|
| 50MG | 1469 | In Stock |
|
| 100MG | 2009 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSutimlimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSutimlimab is a novel monoclonal antibody targeting complement protein C1. Sutimlimab is commonly used as a C1 inhibitor to treat cold agglutina-associated hemolysis.
-
DescriptionSutimlimab, a first-in-class complement protein component 1, s subcomponent (C1s) inhibitor, can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetComplement System
-
RecptorComplement System
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2049079-64-1
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Alexander R?th, et al. Sutimlimab in Cold Agglutinin Disease. N Engl J Med. 2021 Apr 8;384(14):1323-1334.?
molnova catalog
related products
-
LNP023
LNP023 (LNP-023) is a highly potent, reversible, selective inhibitor of factor B (IC50=10 nM).
-
EG01377 2HCl
EG01377 2HCl is a potent, bioavailable and selective inhibitor of neuropilin-1 (NRP1) with a Kd value of 1.32 μM and an IC50 value of 609 nM for both EG01377 2HCl against NRP1-a1 and NRP1-b1.
-
CP-447697
CP-447697, a lipophilic C5a receptor antagonist, exhibits an IC50 of 31 nM. It is utilized in inflammation research.
